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To evaluate the efficacy of an association of N-acetyl cystein, alpha-lipoic acid, and bromelain (NAC/LA/Br) in the treatment
of endometriosis we set up a new in vivo murine model. We explored the anti-inflammatory and proapoptotic effect of this
combination on human endometriotic endothelial cells (EECs) and on endothelial cells isolated from normal uterus (UtMECs).
We implanted fragments of human endometriotic cysts intraperitoneally into SCID mice to evaluate the efficacy of NAC/LA/Br
treatment. UtMECs and EECs, untreated or treatedwithNAC/LA/Br, were activatedwith the proinflammatory stimulus TNF-𝛼 and
their response in terms of VCAM1 expressionwas evaluated.The proapoptotic effect of higher doses ofNAC/LA/Br onUtMECs and
EECs was measured with a fluorogenic substrate for activated caspases 3 and 7. The preincubation of EECs with NAC/LA/Br prior
to cell stimulation with TNF-𝛼 prevents the upregulation of the expression of the inflammatory “marker” VCAM1. Furthermore
NAC/LA/Br were able to induce EEC, but not UtMEC, apoptosis. Finally, the novel mouse model allowed us to demonstrate that
mice treated with NAC/LA/Br presented a lower number of cysts, smaller in size, compared to untreated mice. Our findings
suggest that these dietary supplements may have potential therapeutic uses in the treatment of chronic inflammatory diseases
like endometriosis.
1. Introduction
Endometriosis (EM) is a chronic estrogen-dependent dis-
order characterized by the presence of endometrium-like
tissue outside the uterine cavity. It is associated with dys-
menorrhea, dyspareunia, noncyclic pelvic pain, subfertil-
ity, and infertility [1]. This frequent gynaecological disease
affects 10–15% of women in reproductive age [2]. It is well
accepted that a blood supply is essential for the survival
of endometriotic implants and the development of EM, as
blood is crucial for providing nutrients and growth factors
and for promoting recruitment of inflammatory cells to
the endometriotic lesions, as described by Groothuis [3].
Endometriotic lesions are highly vascularized, and it is now
widely accepted that the formation of new blood vessels
at implantation sites plays a key role in the growth of
endometriotic cells [4]. Furthermore, eutopic endometrium
from women with EM has greater angiogenic potential than
eutopic endometrium from healthy subjects [5]. Since the
growth of newly formed blood vessels is of pivotal importance
in the development of EM, the inhibition of angiogenesis
may offer an opportunity for treatment [6–8]. In this respect,
it is noteworthy that vascular endothelium is known to
play a critical role in regulation of inflammatory processes
[9] and that cell adhesion molecules such as vascular cell
adhesion molecule-1 (VCAM1), as well as proinflamma-
tory cytokines, play key roles in the pathogenesis of EM
[10].
EM can be treated by excising peritoneal implants, deep
nodules, and ovarian cysts. Although lesion eradication is
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considered a fertility-enhancing procedure, the benefit on
reproductive performance is moderate [11]. Surgical removal
of ectopic lesions represents the first line of intervention for
the treatment of EM but is characterized by a relevant per-
centage of recurrences [12]. In addition, a variety of medical
hormonal therapies, that all aimed to reduce the levels of
circulating estrogens, are currently available [13]. However,
these treatments are often unsatisfactory and cannot be used
over long periods of time, due to the occurrence of severe
adverse effects [14].Therefore, new and improved therapeutic
solutions that can efficiently reduce lesions with limited
side effects and no interference with the patient’s fertility
are definitely desirable. In this respect, it has been recently
shown that N-acetyl cysteine (NAC) effectively treats ovarian
endometriosis. In terms of reduction in cysts size, the data
reported by Porpora et al. are even more favorable than those
granted by the currently adopted hormonal treatments, with
the further advantages of fertility preservation and of the
virtual absence of undesired side effects [15].
On these bases, the aim of this study was to investigate
the effects of an association of NAC, alpha-lipoic acid (LA),
and bromelain (Br) in vivo after establishing a novel model
of EM based on the injection of human endometrial tissue in
the peritoneumof SCIDmice. In addition, the of NAC/LA/Br
combinationwas analyzed in vitro onmicrovascular endothe-
lial cells isolated from human endometriotic tissues (EECs)
as well as in microvascular endothelial cells isolated from
human endometrium (UtMECs).
2. Materials and Methods
2.1. Preparation of the Compound Mixture. All components
of the mixture were purchased from Sigma-Aldrich (Milan,
Italy) and solutionswere sterilized by 0.22𝜇mfiltration. Stock
concentrations were 10mg/mL in H
2
O for NAC, 5mg/mL
in absolute ethanol for LA, and Br 1mg/mL in PBS for
Br. NAC and LA solutions were stored at 4∘C while Br at
−20∘C until use. All reagents were tested for sterility and
LPS. For cell culture studies, the three drugs were combined
in complete cell culture medium at a final concentration of
1000 𝜇g/mL NAC + 500𝜇g/mL LA + 50𝜇g/mL Br. In these
conditions, the solution did not form visible precipitates and
pH was stable (measured with pH-Meter BASIC20+, CRI-
SON INSTRUMENT). To choose the optimal concentrations
for the in vitro studies, we have referred to the concentrations
of NAC, LA, and Br, proportionally to those present in the
new dietary supplement Naxend (Pizeta Pharma, Perugia,
Italy; 72.72% NAC, 24.24% LA and 3.03% Br), considering
also their bioavailability, the absorption, and the peak plasma
of each compound.
2.2. Human Tissues. The Maternal-Children’s Hospital (RC
08/13, IRCCS “Burlo Garofolo,” Trieste, Italy) approved this
study, and following informed consent, endometriosis speci-
mens were obtained from women undergoing laparoscopy to
remove endometrial cysts and endometrial tissue was fertile
women undergoing hysterectomy for leiomyomatosis in the
midproliferative and midsecretory phase defined according
to Noyes criteria [16].
2.3. Animals. Female SCID mice (4–6 weeks of age) were
purchased from Charles River (Milan, Italy) and maintained
under pathogen-free conditions. All the experimental proce-
dures involving animals were done in compliance with the
guidelines of the European (86/609/EEC) and the Italian
(D.L.116/92) laws and were approved by both the Italian
Ministry of Health and the Administration of the University
Animal House.
2.4. Animal Model and Ex Vivo Analysis of Cysts. Endometri-
otic tissue from three peritoneal cysts was collected in sterile
PBS and then suspended as coarse fragments, loaded in
3mL syringes, and standardized with respect to volume and
weight. A volume of 0.5mL of cyst suspension approxi-
mately equal to 0.4 g of wet tissue was injected by 16 ga
needle intraperitoneally into SCID mice (Charles River).
Hormonal therapy with 17-𝛽-estradiol-3-benzoate (Sigma-
Aldrich, 30 𝜇g/kg i.m.) was initiated at the time of cyst tissue
injection and at 3-day intervals thereafter. The day after
injection mice were divided randomly in two groups and we
administered only to the first one NAC 250mg/kg/die, LA
125mg/kg/die, and Br 12,5mg/kg/die per os. Twenty-one days
following injection, the animals were killed and implanted
endometriotic lesions in treated (𝑛 = 7) or untreated mice
(𝑛 = 9) were identified, counted, resected, and collected in
formalin 10%.
Endometriotic lesions excised fromSCIDmicewere fixed
in 10% buffered formalin and paraffin embedded. Four-
micrometers-thick sections were stained with Diff-Quick
(Biomap, Milan, Italy) staining (following the manufacturer
instructions) and examined for the presence and distribution
of vessels and glands. For immunohistochemical analysis,
the slides were microwaved three times in Tris-HCl/EDTA
(ethylenediamine tetraacetic acid) pH 9.0 buffer (Dako) for
5min, brought to RT, andwashed in PBS. After neutralization
of the endogenous peroxidase with H
2
O
2
for 10min, the
sections were first incubated with protein block (Dako)
for 10min and then with the primary antibodies for 1 h
at RT (polyclonal rabbit anti-human vWF from Dako).
The bound antibodies were revealed using the horseradish
peroxidase- (HRP-) conjugated anti-rabbit IgG antibodies
(Sigma-Aldrich) and diaminobenzidine (DAB) as substrate
(Dako). Slides were evaluated under Leica DM3000 micro-
scope (Leica, Wetzlar, Germany) and the pictures were
collected using a Leica DFC320 digital camera (Leica).
2.5. Immunofluorescent Staining. Endometriotic tissue frag-
ments approximately 1 cm3 were embedded in OCT (BioOp-
tica, Milan, Italy), snap-frozen in liquid nitrogen, and kept
at −80∘C until use. Cryostat sections of about 6 𝜇m were
air dried, fixed in acetone, and either used immediately or
kept at−80∘C. Binding ofmouse anti-human cytokeratin 8/18
(CK8/18) ormouse anti-human vWF (Dako,Milan, Italy) was
detected by incubating the sections with goat anti-mouse IgG
Cy3-conjugated secondary antibodies 30min at RT, and then
the nuclei were stained blue with DAPI (4󸀠,6-diamidino-2-
phenylindole, Sigma-Aldrich) 1𝜇g/mL.
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2.6. Cell Isolation and Culture. UtMECs and EECs were
isolated and characterized as previously described by Bulla
et al. [17]. Both ECs were positively selected with Dynabeads
M-450 (Life Technologies, Milan, Italy) coated with Ulex
europaeus 1 lectin (Sigma-Aldrich), seeded on 12,5 cm2 flask
precoated with 2 𝜇g/cm2 fibronectin (Roche, Milan, Italy),
andmaintained in serum-free endothelial basalmedium (Life
Technologies, Monza, Italy) supplemented with 20 ng/mL
bFGF (basic Fibroblast Growth Factor), 10 ng/mL EGF (Epi-
dermal Growth Factor), 10% FCS (all from Life Technolo-
gies), and 10% human serum and incubated at 37∘C, 5% CO
2
.
The purity of the resulting EC populations was more than
98% as verified by staining with antibodies to VWF, CD105,
VE cadherin (Dako, Milano, Italy), and CD31/PECAM-1
kindly provided by M. R. Zocchi (San Raffaele Hospital,
Milan, Italy).
2.7. Immunofluorescence on Endothelial Cells. ECs were
plated in 8-chamber culture slides (BDBiosciencesDiscovery
Labware, Milan, Italy) coated with 2 𝜇g/cm2 fibronectin
(Roche) and incubated at 37∘C in CO
2
enriched atmosphere.
When cells grew to confluence, they were fixed and perme-
abilized with FIX & PERM cell permeabilization kit (Societa`
ItalianaChimici, Rome, Italy).Then cells were incubatedwith
primarymAb, (cloneF8/86)mouse anti-human vWF (Dako),
or mouse anti-human CD31 (Immunotools, Germany) for 1 h
at room temperature (RT) followed by FITC-conjugated goat
anti-mouse IgG for 1 h at RT. Images were acquiredwith Leica
DM3000 microscope (Leica) and the pictures were collected
using a Leica DFC320 digital camera (Leica).
2.8. Cytofluorimetric Analysis. ECs were detached from cul-
ture flasks with 5mM EDTA at 37∘C and a total number of 5
× 105 were fixed with FIX & PERM cell permeabilization kit
(Societa` Italiana Chimici) and incubated in permeabilization
solution in ice for 30󸀠 with mAb (clone 9) mouse anti-
human vimentin (Sigma-Aldrich), mAb (cloneF8/86) mouse
anti-human vWF, or mAb (cloneV9) mouse anti-human
CK8/18. The binding of primary antibodies was detected by
incubation with FITC-conjugated goat anti-mouse IgG. The
membrane antigens were detected on unfixed cells, using
monoclonal anti-human CD31, CD45, CD34, and CD105
directly FITC-conjugated, all purchased from Immunotools
(Germany). The cells were fixed with 1% paraformalde-
hyde (Sigma-Aldrich) and analyzed for fluorescence with
a FACScalibur instrument (BD Falcon, Milan, Italy) using
CellQuest software.
2.9. Whole Cell VCAM1 ELISA. Both types of cells were
grown to the confluence in 96-well plates and incubated with
drugs (concentration of NAC 10 𝜇g/mL, LA 9𝜇g/mL, and
Br 2𝜇g/mL), alone or in association, for 48 h 37∘C 5% CO
2
.
Successively the cells were stimulated overnight with TNF-
𝛼 (100 ng/mL), washed with Dulbecco’s PBS added with 2%
BSA (Bovine Serum Albumine, fraction V, Sigma-Aldrich)
and CaCl
2
-MgCl
2
0,7mM (Sigma-Aldrich), and then incu-
batedwithmousemAb anti-humanVCAM1 (Sigma-Aldrich)
5 𝜇g/mL for 90min at RT. The binding of primary anti-
body was reveled incubating the cells with a polyclonal
anti-mouse IgG conjugated with alkaline phosphatase. The
enzymatic reactionwas developedwith PNPP (p-nitrophenyl
phosphate) (Sigma-Aldrich; 1mg/mL) as substrate and read
kinetically at 405 nmusing aTitertekMultiskanELISA reader
(Flow Labs, Milano, Italy).
2.10. Apoptosis Assay. Both types of cells were grown to
80% of confluence in 96-well plates and incubated with the
compounds, alone or in association, for 72 h 37∘C. After then
cells were incubated with 5𝜇M of CellEvent Caspase-3/7
Green Detection Reagent (Life Technologies), a fluorogenic
substrate for activated caspases 3 and 7. The reagent consists
of a four amino acid peptide (DEVD) conjugated to a nucleic
acid binding dye. This cell-permeant substrate is intrinsically
nonfluorescent, because the DEVD peptide inhibits the abil-
ity of the dye to bind to DNA. After activation of caspase-3
or caspase-7 in apoptotic cells, the DEVD peptide is cleaved,
enabling the dye to bind to DNA and produce a bright,
fluorogenic response with an absorption/emission maxima
of ∼502/530 nm. The fluorescence data were acquired with
TECAN Infinite200 and normalized for total protein present
in each well. For the protein quantitation the cells were then
lysed with NaOH 1M and evaluated by Bradford assay as
previously reported [18].
3. Statistical Analysis
For each set of experiments, values are reported as means ±
SE. The results were evaluated by using the Mann-Whitney
test. Statistical significance was defined as 𝑃 < 0.05.
4. Results
4.1. Establishment of a Relevant In Vivo Model for EM and
Efficacy of the NAC/LA/Br Combination in Decreasing the
Number of Cysts Formation In Vivo. The primary aim of our
study was the evaluation of the effect of NAC/LA/Br in a rel-
evant model of EM. For this purpose, we set up a new mouse
model, modifying the animal model described by Awwad
and colleagues [19] and by Grummer and colleagues [20].
Specifically, we used human endometriotic tissue obtained
from ovarian cysts instead of normal human endometrium to
create the endometriotic lesions into the peritoneal cavity of
SCID mice. Endometriotic tissue from three peritoneal cysts
was injected in the peritoneal cavity of SCIDmice. Hormonal
therapy with 17-𝛽-estradiol-3-benzoate was initiated at the
time of injection and at intervals of 3 days thereafter. Twenty-
one days following injection, the animals were killed and
implanted endometriotic lesions were identified, analyzed,
and characterized. This protocol provided an implantation
rate of 100% and the dimension and the histology of these
cysts were evaluated. Excised explants revealed the presence
of EM-like features upon histologic examination, that is,
stroma and endometrial glands. All the implants showed
a well restructured columnar and/or cuboidal glandular
epithelium with cytogenetic stroma. A nascent capillary
network was present at the interface between the implant
and the underlying murine tissue. The presence of new
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vessels, indicated with black arrows in Figure 1(a), was con-
firmed by immunohistochemistry, staining the sections with
anti-vWF polyclonal antibodies (Figure 1(b)). For these in
vivo experiments, we treated the animals daily with NAC
(250mg/kg), LA (125mg/kg), andBr (12,5mg/kg) provided in
the animals’ water bottles, a per os administration thatmimics
human dosing [21]. To choose the optimal concentrations of
NAC, LA, and Br, we have referred to the concentrations of
NAC, LA, and Br, proportionally to those present in the new
dietary supplement Naxend (Pizeta Pharma, Perugia, Italy;
72.72% NAC, 24.24% LA, and 3.03% Br).
As shown in Figure 1(c), all control group animals devel-
oped at least 1 cyst, with up to 4 in some control animals. In 4
mice treated with the NAC/LA/Br combination, no cyst was
visible and in 3 mice only 1 cyst was present. The number of
cysts developing in treated compared to untreated animals
was significantly (𝑃 < 0.05) lower (Figure 1(d)). It is also
noteworthy that the cysts present in the untreated animal
were larger than those in the treated mice.
4.2. Isolation and Characterization of Endometriotic Endothe-
lial Cells (EECs) and Evaluation of Their In Vitro Response
to the NAC/LA/Br Combination. Since endothelial cells play
a significant role in the development of endometriotic
lesions [4], as also confirmed in our animal model, we next
developed a new protocol for the isolation and culture of
endothelial cells from human endometriotic ovarian cysts.
For this purpose, the presence and the density of the vessels
inside human endometriotic cysts were initially analyzed by
immunofluorescence on sections of human endometriotic
tissues. The sections were stained with mAb anti-human
vWF, a classical endothelial cell marker, and with CK8/18,
in order to evidence the presence of endometriotic glands.
Figure 2 clearly shows the presence of several vessels inside
the cysts and the presence of one representative gland.
These samples were then used to isolate the endothelial
cells. The isolated endothelial cells cultured on fibronectin
easily reach confluence within few days. The morphology of
cultured EECs stained with mAb anti-CD31, another typical
marker of endothelial cells, is shown in Figure 3. We then
characterized EECs by cytofluorimetric analysis in order to
evaluate the purity of these cells and to exclude the presence
of contaminating cells. 100% of these cells were positive for
classical endothelial cell markers (CD31, CD105, vWF, and
vimentin) and 80% were positive for CD34, a marker for
newly formed vessels (Figure 3). Cultured EECs were devoid
of expression of the epithelial marker CK8/18 and leukocyte
marker CD45. Consistent results were obtained for EEC
populations derived from five different patients.
4.3. NAC/LA/Br Exerts Anti-Inflammatory Effect Reducing the
Expression of VCAM1 in TNF-𝛼 Stimulated EECs. In next
group of experiments, EECs from 5 distinct patients were
grown to confluence and then stimulated with 100 ng/mL of
the proinflammatory cytokine TNF-𝛼 in order to upregulate
the expression of the adhesion molecule VCAM1 [22], which
represent a proinflammatory marker. We compared the total
amount of VCAM1 by ELISA on EECs untreated, EECs stim-
ulated for 12 hours with TNF-𝛼, and cells treated with TNF-𝛼
previously preincubated for 72 hours with NAC, LA, and Br,
(NAC 10 𝜇g/mL, AL 9 𝜇g/mL, and Br 2 𝜇g/mL) used alone
or in association. No reduction in VCAM1 expression was
observed in cells treated with individual drugs (Figure 4(a)).
Only the drug combination exerted a statistically (𝑃 <
0.05) significant although incomplete decrease of VCAM1
levels as compared to TNF-𝛼-treated cultures. For compar-
ison, we have used endothelial cells isolated from normal
human endometrium fromwomen undergoing hysterectomy
(UtMECs) [17]. As shown in Figure 4(b), the downregulation
of VCAM1 in TNF-𝛼-treated UtMECs was complete in the
presence of the combination of NAC + Br + LA (MIX). The
addition of NAC/LA/Br to the endothelial cell culture media
did not alter the medium pH and no effect to the cell viability
was observed for ECs treated with the same concentrations
of compounds as assessed by trypan blue staining (data not
shown).
4.4. NAC/LA/Br Combination Selectively Exerts Proapoptotic
Activity on EECs. In order to evaluate whether besides the
anti-inflammatory activity the NAC, LA, and Br mixture
might also affect endothelial cell viability, EECs were plated
on 8-chamber culture slides, grown to 80% confluence, and
incubated for 72 h with NAC, LA, and Br (NAC 20𝜇g/mL,
AL 18 𝜇g/mL, and Br 4 𝜇g/mL) used alone or in combination.
As shown in Figures 5(a)-5(b), EECs incubated with the
mixture of compounds showed a decreased number of viable
cells as compared to untreated cultures. Based on these
results, we then investigated the ability of NAC/LA/Br to
induce apoptosis. Both EECs and UtMECs were incubated
with a fluorogenic substrate for activated caspases 3 and 7
and the fluorescence values obtained were normalized for
total protein present in each well. As shown in Figure 5(c),
treatment of the cells with the NAC/LA/Br mixture, at
these higher concentrations, was able to induce a statistically
significant (𝑃 < 0.05) increase of apoptosis of EECs. In fact,
the induction of caspase activity induced by the drug com-
bination was comparable to that of positive control (H
2
O
2
).
Of note, the NAC/LA/Br mixture was totally ineffective in
UtMECs (Figure 5(d)).
5. Discussion
Most recent guidelines for the treatment of endometriosis-
associated symptoms recommend to surgically treat endo-
metriosis, as this is effective for reducing endometriosis-
associated pain for those in whom medical treatment has
failed [23]. Medical treatments for EM are usually aimed at
reducing the production of endogenous estrogens or induc-
ing endometrial differentiation with progestins. The pain
associated with endometriosis is usually treated initially with
oral contraceptive agents or non-steroidal anti-inflammatory
drugs, because these agents have fewer side effects and are less
expensive than other treatment options. GnRH agonists, as
well as other agents such as danazol or progestational agents,
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Figure 1: NAC/LA/Br reduces the number and the dimension of cysts in a new in vivo model of EM. (a) Histochemical analysis of an
endometriotic lesion in mice with Diff-Quick staining. Original Magnification 100x. (b) Immunohistochemical analysis of a cyst excised
from the peritoneum of mice. Sections were stained with rabbit anti-vWF followed by a secondary antibody to rabbit IgG HRP conjugated
and revealed with DAB. The inset showed the staining obtained with only secondary antibody. Original Magnification 100x. (c) Number of
cysts counted in untreatedmice (𝑛 = 9) or treated with NAC 250mg/kg/die, AL 125mg/kg/die, and Br 12,5mg/kg/die (𝑛 = 7). Mann-Whitney
test 𝑃 < 0.001. (d) Representative image of the different morphological appearance of cysts in treated or untreated SCID mice.
Figure 2: Immunofluorescence analysis of human endometriotic cysts. The frozen sections were stained with mAb anti-human vWF to
highlight the vessels or with mAb anti-human CK 8/18 to show the glands. The binding of mouse monoclonal antibodies was revealed by
the incubation with goat anti-mouse IgG Cy3-conjugated secondary antibodies. Nuclei were stained in blue by DAPI: original magnification
100x.
and, recently, aromatase inhibitors are usually reserved for
use if the first-line agents fail to provide an acceptable
degree of relief. These agents represent standard therapies
for EM but are associated with long-term side effects [14].
Although currently available medical therapies are not cura-
tive per se, they are important for pain suppression and
lesion regression. Thus, efforts are still being focused on the
improvement and promotion of new treatments with higher
efficacy and fewer side effects. A high number of medications
have been tested in preclinical models of endometriosis
due to their theoretical capacity of disrupting important
pathophysiologic pathways of the disease, such as inflamma-
tory response, angiogenesis and cell survival, proliferation,
migration, adhesion, and invasion. TNF-𝛼 blockers, nuclear
factor kB inhibitors, antiangiogenic agents, statins, antioxi-
dants, immune-modulators, flavonoids, histone deacetylase
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Figure 3: Characterization of the purity of endothelial cells isolated from endometriotic tissue. (A) EECs were characterized by
cytofluorimetric analysis for the expression of CD45, CD34, CD31, CD105, vWF, and vimentin, and the expression of these markers (green
lines)was comparedwith correlated control antibodies (black lines).The expression of vWFandCD31was confirmedby immunofluorescence,
on EECs grown to confluence in 8-chamber culture slides. After fixation and permeabilization the cells were stained with mAb anti-human
CD31 or anti-vWF.The binding of mouse monoclonal antibodies was revealed by the incubation with goat anti-mouse IgG FITC-conjugated
secondary antibodies. Nuclei were stained in blue by DAPI: original magnification 200x.
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Figure 4: Anti-inflammatory effect of NAC/LA/Br on ECs: analysis of VCAM1 expression. Five different populations of endometriotic
endothelial cells (EECs) and 5 different populations of uterine microvascular endothelial cell (UtMECs) were isolated, as described by Bulla
et al. [17] with some modifications. ECs were grown to confluence in a 96-well plate and then incubated with NAC 10𝜇g/mL, AL 9 𝜇g/mL,
and Br 2𝜇g/mL, alone or in association (MIX). Successively the cells were stimulated overnight with TNF-𝛼 (100 ng/mL) and incubated with
anti-human VCAM1.The binding of primary antibody was revealed incubating the cells with a goat anti-mouse IgG conjugated with alkaline
phosphatase. The 100% of VCAM1 expression is referred to the TNF-𝛼-treated cells. Data are expressed as mean ± SE of results from five
experiments each performed in triplicate. ∗𝑃 < 0.05 with respect to the untreated (Mann-Whitney test).
inhibitors, matrix metalloproteinase inhibitors, metformin,
novel modulators of sex steroids expression, and apoptotic
agents were all effective in vitro and/or in animal models.
Most of these agents did not reach the clinical setting, mainly
because of the high risk of adverse effects [24].
An alternative approach for treatment of EM is repre-
sented by anti-inflammatory compounds [11]. In particular,
Pittaluga and colleagues [25] and Onalan et al. [26] recently
demonstrated the efficacy of NAC in two different in vivo
models of EM. No data are available on the use of LA
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Figure 5: Evaluation of the proapoptotic effect of NAC/LA/Br on ECs. (a), (b) Morphologic appearance of EECs untreated (a) or incubated
with NAC 20 𝜇g/mL, AL 18 𝜇g/mL, and Br 4𝜇g/mL in association (MIX) (b). (c), (d) Both types of cells were grown to 80% of confluence
in 96-well plates and incubated with NAC 20𝜇g/mL, AL 18 𝜇g/mL, and Br 4 𝜇g/mL, alone or in association (MIX), for 72 h 37∘C. The cells
were then incubated with 5𝜇M of CellEvent Caspase-3/7 Green Detection Reagent (Life Technologies), a fluorogenic substrate for activated
caspases 3 and 7. The fluorescence data were normalized for the total protein present in each well. Data are expressed as mean ± SE of results
from three experiments each performed in triplicate. ∗𝑃 < 0.05 with respect to the untreated (Mann-Whitney test).
and Br for the treatment of EM but they are currently in
clinical use for the treatment of inflammatory diseases [27,
28]. Endometriotic lesions are highly vascularized, and it
is now widely accepted that the formation of new blood
vessels in implanted places plays a key role in the growth of
endometriotic cells [4]. The growth of newly formed blood
vessels is of pivotal importance in the development of EM,
so inhibition of angiogenesis may offer a new opportunity
for treatment [29]. Therefore, in this study we have proposed
an innovative in vitro model to study the efficacy of a new
treatment for EM, based on the analysis of endometriotic
endothelial cell response, in consideration of the key role
of endothelial cells in controlling inflammation and angio-
genesis. A first important achievement of our study was
the establishment of a novel mouse model based on the
intraperitoneal injection of endometriotic human tissue in
SCID mice. In analogous models available in the literature,
fragments of human endometriotic cysts were surgically fixed
to the peritoneal wall [20]. The benefit of our model is that
our procedures reduce animal suffering and animal losses.
The fact that all treated animals developed at least one cyst is
a profoundly beneficial aspect of this model. Immunohisto-
chemical observations indicated that the tissue excised from
murine peritoneumdeveloped several new vessels, indicating
that the cysts had a morphological organization similar to
human cysts with new blood vessel formations. Thanks to
the development of this mouse model we have been able to
demonstrate the effectiveness of NAC/LA/Br in vivo with the
result that treated mice presented a lower number of cysts,
which were also smaller in size than those in untreated mice.
A second important finding of our study was the
successful isolation of pure endothelial cells from human
endometriotic lesions. Using these cells to set up an in vitro
model that exploits the endothelial cells is preferable, since
many differences exist between endothelial cells isolated from
different sites [30]. Our results indicated that when used
alone the three studied compounds are able to induce only
a modest or null inhibition of TNF-𝛼 activation of VCAM1
and a strong inhibitionwhen used in combination, suggesting
the presence of an additive effect of the three compounds.
In line with our current data previous findings obtained on
hypertensive patients (with type 2 diabetes) treatedwithNAC
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experienced reduction of C-reactive protein, intracellular
adhesion molecule, and vascular cell adhesion molecule
[31]. In addition, Tisato et al. documented that LA signifi-
cantly decreased the baseline levels of PDGF, RANTES, and
CXCL10 expression and counteracted TNF-𝛼-induced NF-B
and p38/MAPK activation in endothelial cells from chronic
venous disease patients [27]. A second important finding of
our study was the ability of NAC/LA/Br to promote apoptosis
in EEC. In this respect, it should be underlined that the in
vitro behavior of UtMECs was different as these cells were
totally unaffected by the NAC/LA/Br combination in terms
of apoptosis induction. These findings underline the impor-
tance not only of tissue-specificity but also of pathological
specificity of endothelial cells. This might explain the partial
discrepancies of our current data with those of Cai et al.
[32] and Mohr and Desser [33] which, respectively, indicated
that Br inhibits endothelial cell invasion and angiogenesis,
while Larghero et al. [34] demonstrated that LA induced
apoptosis through the production of the proapoptotic TNF-
alpha-related apoptosis-inducing ligand (TRAIL) cytokine in
endothelial cells [34].
6. Conclusions
In conclusion, we have adopted an improved in vivomodel of
EM,which reduces animal suffering by nonsurgical implanta-
tion of tissue fromhuman cysts.Moreover, EECs are a unique,
human-derived, easily available, in vitro model of EM that
may advance study of the inflammatory process and the role
of angiogenesis in endometriosis.Thanks to thesemodels, we
could demonstrate that NAC/LA/Br is an effective treatment
for EM that may have potential therapeutic uses in the
prevention and treatment of patients. It would be interesting
in a further study to compare the effect of NAC/LA/Br with
standard therapies and to evaluate if the use of NAC/LA/Br
in combination with standard therapies may lead to the
improvement of the standard medical treatment for EM.
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